The partners are planning to integrate the technology into Horizon's research tools and services and to develop it for applications in cell therapeutics.
With several SBIR grants from the NIH, the firm is also using its Liquid Scan platform to identify neonatal trophoblast cells in maternal blood samples.
Despite initial promise, NGS-based MRD detection has not been broadly adopted, but improvements in technology and more clinical utility data may change that.
In an epigenome-wide association study, researchers uncovered more than 1,000 sex-related differentially methylated positions among chronic lymphocytic leukemia patients.
The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
